Hormonal
Abdominal obesity, measured by waist circumference and waist-to-hip ratio, is a strong independent risk factor for colon cancer and large adenomas, increasing risk even after adjusting for overall body mass index and physical activity levels.
Monitor your waist size and waist-to-hip ratio, not just your weight. Abdominal fat is a strong independent risk factor for colon cancer. Maintaining a healthy waist circumference (e.g., <35 inches for men in this study's reference group) and reducing abdominal adiposity through lifestyle changes can significantly lower your risk.
Waist circumference and waist-to-hip ratio were strong risk factors for colon cancer... These associations persisted even after adjustment for body mass and physical activity.
Why this rating
Prospective cohort data with specific anthropometric measurements and adjustment for confounders.
Source
Physical Activity, Obesity, and Risk for Colon Cancer and Adenoma in Men
Edward L. Giovannucci et al. · Annals of Internal Medicine · 1995
DOI 10.7326/0003-4819-122-5-199503010-00002
More from this paper
- Higher levels of leisure-time physical activity are associated with a significantly reduced risk of developing colon cancer in men, with those in the highest activity quintile having approximately half the risk of those in the lowest.Good
- The combination of high body mass index and low physical activity results in a substantially elevated risk of colon cancer, significantly higher than either factor alone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →